Concomitant Pulmonary Tuberculosis Impair Survival in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Lung Adenocarcinoma Patients Receiving EGFR-Tyrosine Kinase Inhibitor

Concomitant Pulmonary Tuberculosis Impair Survival in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Lung Adenocarcinoma Patients Receiving EGFR-Tyrosine Kinase Inhibitor

Yalin Xie,1 Ning Su,1 Wei Zhou,2 An Lei,1 Xiang Li,3 Weiwei Li,4 Zhan Huang,4 Wenchang Cen,1 Jinxing Hu5 1Department of Oncology, Guangzhou Chest Hospital, Guangzhou, People’s Republic of China; 2Department of Pathology, Guangzhou Chest Hospital, Guangzhou, People’s Republic of China; 3Department of...

Full description

Bibliographic Details
Main Authors:	Xie Y, Su N, Zhou W, Lei A, Li X, Li W, Huang Z, Cen W, Hu J
Format:	Article
Language:	English
Published:	Dove Medical Press 2021-10-01
Series:	Cancer Management and Research
Subjects:	advanced lung adenocarcinoma pulmonary tuberculosis egfr mutation egfr-tyrosine kinase inhibitors prognosis
Online Access:	https://www.dovepress.com/concomitant-pulmonary-tuberculosis-impair-survival-in-advanced-epiderm-peer-reviewed-fulltext-article-CMAR

Similar Items

Clinical efficacy evaluation of tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations
by: Song X, et al.
Published: (2017-06-01)

Different mutational characteristics of the subsets of EGFR-tyrosine kinase inhibitor sensitizing mutation-positive lung adenocarcinoma
by: Eun Young Kim, et al.
Published: (2018-12-01)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
by: Xu H, et al.
Published: (2019-07-01)

Oncogenic Fusions May Be Frequently Present at Resistance of EGFR Tyrosine Kinase Inhibitors in Patients With NSCLC: A Brief Report
by: Diego Enrico, MD, et al.
Published: (2020-06-01)

EGFR-Mutated Breast Metastasis of Lung Adenocarcinoma: A Case Report
by: Eric Dansin, et al.
Published: (2015-03-01)

Kinase-Inactivated EGFR Is Required for the Survival of Wild-Type EGFR-Expressing Cancer Cells Treated with Tyrosine Kinase Inhibitors
by: Rintu Thomas, et al.
Published: (2019-05-01)

Concurrent chemotherapy and first‐generation epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors (TKIs) with or without an antiangiogenic agent as first‐line treatment in advanced lung adenocarcinoma harboring an EGFR mutation
by: Ziyi Xu, et al.
Published: (2021-08-01)

Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence
by: Wang X, et al.
Published: (2016-09-01)

A preliminary results of integrated chemotherapy with EGFR receptor tyrosine kinase inhibitors in patients with non-small-cell-lung cancer harboring EGFR mutation
by: K. K. Laktionov, et al.
Published: (2019-06-01)

The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients
by: Anna Maria Rachiglio, et al.
Published: (2019-03-01)

EGFR Thr790Leu as a Potential Resistance Mechanism to First-Generation EGFR Tyrosine Kinase Inhibitor May Respond to Osimertinib in Patients With Lung Adenocarcinoma
by: Chan Xiang, PhD, et al.
Published: (2021-07-01)

Impact of Radiotherapy Pattern on the Prognosis of Stage IV Lung Adenocarcinomas Harboring EGFR Mutations
by: Zhang Y, et al.
Published: (2021-04-01)

Design, Synthesis, and Evaluation of Ribose-Modified Anilinopyrimidine Derivatives as EGFR Tyrosine Kinase Inhibitors
by: Xiuqin Hu, et al.
Published: (2017-11-01)

A case report of EGFR mutant lung adenocarcinoma that acquired resistance to EGFR-tyrosine kinase inhibitors with T790M mutation and epithelial-to-mesenchymal transition
by: Nana Zhang, et al.
Published: (2017-01-01)

Prognostic implications of immunohistochemistry markers for EGFR-TKI therapy in Chinese patients with advanced lung adenocarcinoma harboring EGFR mutations
by: Zhang R, et al.
Published: (2016-01-01)

EGFR-TKI plus bevacizumab as maintenance therapy for advanced lung adenocarcinoma: a retrospective study of 192 cases
by: HU Xueting, et al.
Published: (2021-04-01)

Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors
by: Keunchil Park, MD, PhD, et al.
Published: (2021-09-01)

ALGORITHMS FOR MANAGEMENT OF PATIENTS WITH ADVERSE EVENTS ON THERAPY WITH TYROSINE KINASE INHIBITORS EGFR
by: D. D. SAKAEVA
Published: (2017-06-01)

AFATINIB IN THE TREATMENT OF METASTATIC AND LOCALLY ADVANCED LUNG ADENOCARCINOMA WITH EGFR MUTATIONS: NEW SIDES STUDIED POSSIBILITIES
by: E. V. Karabina, et al.
Published: (2017-11-01)

Targeting the Epidermal Growth Factor Receptor in EGFR-Mutated Lung Cancer: Current and Emerging Therapies
by: Karam Khaddour, et al.
Published: (2021-06-01)

Lung Adenocarcinoma with Pulmonary Miliary Metastases and Complex Somatic Heterozygous EGFR Mutation
by: Alexandre Schaller, et al.
Published: (2014-11-01)

Prognostic Analysis of EGFR-TKIs Combined with Gamma Knife in EGFR-mutant Lung Adenocarcinoma with Brain Metastasis
by: Limin CHEN, et al.
Published: (2019-05-01)

Outcome of uncommon EGFR mutation positive newly diagnosed advanced non-small cell lung cancer patients: a single center retrospective analysis
by: Kate S, et al.
Published: (2019-01-01)

Identification of Vinyl Sulfone Derivatives as EGFR Tyrosine Kinase Inhibitor: In Vitro and In Silico Studies
by: Thitinan Aiebchun, et al.
Published: (2021-04-01)

Molecular Targeting of Epidermal Growth Factor Receptor (EGFR) and Vascular Endothelial Growth Factor Receptor (VEGFR)
by: Nichole E. M. Kaufman, et al.
Published: (2021-02-01)

Efficacy of EGFR‐TKIs with or without upfront brain radiotherapy for EGFR‐mutant NSCLC patients with central nervous system metastases
by: Yu Saida, et al.
Published: (2019-11-01)

Lung Adenocarcinoma Patient Harboring EGFR-KDD Achieve Durable Response to Afatinib: A Case Report and Literature Review
by: Lingling Zhao, et al.
Published: (2021-04-01)

Recent advances in 4-aminoquinazoline based scaffold derivatives targeting EGFR kinases as anticancer agents
by: Rania S.M. Ismail, et al.
Published: (2016-06-01)

Durable response to EGFR tyrosine kinase inhibitors in a patient with non–small cell lung cancer harboring an EGFR kinase domain duplication
by: Esuteru Hirokawa, et al.
Published: (2021-08-01)

Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with <i>EGFR</i> Mutations
by: Kenichi Suda, et al.
Published: (2021-06-01)

The relationship between Epidermal Growth Factor Receptor (EGFR) mutation and computed tomography findings in lung adenocarcinoma
by: Agnes Septiani, et al.
Published: (2019-08-01)

Rate of EGFR mutation in patients with pulmonary adenocarcinoma
by: Waqas Shuaib, et al.
Published: (2014-12-01)

Successful treatment of triple EGFR mutation T785A/L861Q/H297_E298 with afatinib
by: Vito Longo, et al.
Published: (2021-07-01)

Cecal Volvulus as a Rare Complication of Osimertinib Dosed at 160 mg in Patients With EGFR-Mutant Non-small Cell Lung Cancer
by: Tejas Patil, et al.
Published: (2020-04-01)

Third‐generation EGFR inhibitor HS‐10296 in combination with famitinib, a multi‐targeted tyrosine kinase inhibitor, exerts synergistic antitumor effects through enhanced inhibition of downstream signaling in EGFR‐mutant non‐small cell lung cancer cells
by: Mi Zhang, et al.
Published: (2021-04-01)

ПРИОБРЕТЕННАЯ РЕЗИСТЕНТНОСТЬ К ИНГИБИТОРАМ ТИРОЗИНКИНАЗЫ EGFR: ПУТИ ПРЕОДОЛЕНИЯ
Published: (2017-11-01)

Treatment of EGFR positive lung adenocarcinoma in a heart transplanted patient
by: Ana Hecimovic, et al.
Published: (2019-05-01)

Detection of EGFR Mutations in Cerebrospinal Fluid of EGFR-Mutant Lung Adenocarcinoma With Brain Metastases
by: Liang Shi, et al.
Published: (2021-03-01)

Estrogen Receptor β1 Expression Patterns Have Different Effects on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors’ Treatment Response in Epidermal Growth Factor Receptor Mutant Lung Adenocarcinoma
by: Lijuan Zhang, et al.
Published: (2021-01-01)

Identification of Candidate Biomarkers for EGFR-T790M Drug-resistant  Gene Mutation in Advanced Lung Adenocarcinoma
by: Lijuan CHEN, et al.
Published: (2020-11-01)

Cannot write session to /tmp/vufind_sessions/sess_ahsra8on7ifcel9upls2c39ppd